Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 5;7(9):1885–1898. doi: 10.1182/bloodadvances.2022008798

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 6. — TCRvβ-CARTs specifically reduce tumor burden in vivo. (A) Experimental setup of the in vivo experiment with a homogenous target population. (B) Quantification of luminescence and survival of mice (n = 5 per group) (∗∗∗P = .0008 by mixed-effects analysis, ∗∗P = .0039 by Gehan-Breslow-Wilcoxon test). (C) In vivo imaging system imaging of tumor cells after treatment with TCRvβ12-CARTs (left) or TCRvβ9-CARTs (right) over the course of the experiment. (D) Representative dot plots of CD3⁺CD4⁺CD8⁺TCRvβ12⁺ SupT1s identified in brain tissue collected at the respective end points. (E) Experimental setup of the in vivo experiment with a heterogeneous target population. (F) Representative dot plots of CD8⁺CD4⁺ SupT1s identified in brain tissue collected 24 days after T-cell infusion. Each plot represents an individual mouse. (G) Quantified TCRvβ12- and TCRvβ9-expressing cells within the identified SupT1s in all mice measured by flow cytometry. (H) Representative plots of TCRvβ12 and TCRvβ9 expression of the identified SupT1s (n = 5 per group). APC, activated protein C; FSC, forward scatter.

Figure 6. — TCRvβ-CARTs specifically reduce tumor burden in vivo. (A) Experimental setup of the in vivo experiment with a homogenous target population. (B) Quantification of luminescence and survival of mice (n = 5 per group) (∗∗∗P = .0008 by mixed-effects analysis, ∗∗P = .0039 by Gehan-Breslow-Wilcoxon test). (C) In vivo imaging system imaging of tumor cells after treatment with TCRvβ12-CARTs (left) or TCRvβ9-CARTs (right) over the course of the experiment. (D) Representative dot plots of CD3⁺CD4⁺CD8⁺TCRvβ12⁺ SupT1s identified in brain tissue collected at the respective end points. (E) Experimental setup of the in vivo experiment with a heterogeneous target population. (F) Representative dot plots of CD8⁺CD4⁺ SupT1s identified in brain tissue collected 24 days after T-cell infusion. Each plot represents an individual mouse. (G) Quantified TCRvβ12- and TCRvβ9-expressing cells within the identified SupT1s in all mice measured by flow cytometry. (H) Representative plots of TCRvβ12 and TCRvβ9 expression of the identified SupT1s (n = 5 per group). APC, activated protein C; FSC, forward scatter.